Onco Wiki / Enfermedad

Carcinoma de células escamosas vaginales y vulvares

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-VULVAR-VAGINAL-SCC
TipoEnfermedad
Aliaces
CSC vulvar asociado al VPHCCC derivado de escleroso líquidoCCC derivado de VINEl CSC vaginalCSC de las aves de corralПлоскоклітинна карцинома вульви та піхви
Situaciónreviewed 2026-05-18 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-IARC-MONO-100B-2012 SRC-NCCN-CERVICAL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology8070/3
icd_o_3_topography["C51", "C52"]
icd_10C51, C52
who_classificationWHO Female Genital Tumours 5th ed (2020): Vulvar SCC (HPV-associated + HPV-independent) and Vaginal SCC

Capacidades

Notas

Two biological subgroups managed similarly anatomically but with distinct prevention implications: HPV-driven (vaccination prevents precursor lesions; screening with vulvar exam + biopsy of any persistent lesion) vs HPV-independent (lichen sclerosus surveillance is the dominant prevention modality; topical clobetasol may reduce malignant transformation in select cohorts). Treatment: early-stage — wide local excision ± inguinal sentinel node biopsy (GROINSS-V paradigm replacing routine complete inguinofemoral lymphadenectomy); locally advanced — definitive chemoradiation (cisplatin + RT); metastatic — pembrolizumab if PD-L1+ (KEYNOTE-158 cohort). Vaginal SCC managed similarly with RT-based approaches (anatomic constraints limit surgical options).

Utilizado por

Algoritmos

Enfermedad

Indicación

Señal de alerta

Fuentes